Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the growth of renal cysts that ultimately destroy kidney function. Mutations in the PKD1 and PKD2 genes cause ADPKD. Their protein products, polycystin-1 (PC1) and polycystin-2 (PC2) have been proposed to form a calcium-permeable receptor-channel complex; however the mechanisms by which they function are almost completely unknown. Most mutations in PKD1 are truncating loss-of-function mutations or affect protein biogenesis, trafficking or stability and reveal very little about the intrinsic biochemical properties or cellular functions of PC1. An ADPKD patient mutation (L4132D or DL), resulting in a single amino acid deletion in a putative G-protein binding region of the PC1 C-terminal cytosolic tail, was found to significantly decrease PC1-stimulated, G-protein-dependent signaling in transient transfection assays. Pkd1 DL/DL mice were embryo-lethal suggesting that DL is a functionally null mutation. Kidney-specific Pkd1 DL/cond mice were born but developed severe, postnatal cystic disease. PC1 DL protein expression levels and maturation were comparable to those of wild type PC1, and PC1 DL protein showed cell surface localization. Expression of PC1 DL and PC2 complexes in transfected CHO cells failed to support PC2 channel activity, suggesting that the role of PC1 is to activate G-protein signaling to regulate the PC1/PC2 calcium channel.
Introduction
ADPKD cyst growth leads to massive kidney enlargement and ultimately to renal failure. Mutations in the PKD1 gene cause $85% of ADPKD cases and those in the PKD2 gene $15% of ADPKD cases (1) (2) (3) . PKD1 and PKD2 encode PC1 and PC2, respectively.
PC1 is a large (4 303 aa) integral protein with a > 3 000 aa Nterminal extracellular domain, 11 membrane-spanning domains and a smaller C-terminal cytosolic domain of about 200 aa (4) . PC1 is related to the adhesion-GPCRs and has structural features consistent with it being a membrane receptor (3, 5) . PC2 (TRPP2) is a member of the transient receptor potential (TRP) family of membrane channels (6) . PC2 has nonspecific cation channel activity and acts as a Ca 2þ -regulated Ca 2þ channel (7, 8) . PC2 has also been shown to be an ER Ca 2þ release channel that functions in an IP 3 receptor-dependent fashion (9) . The C-tails of PC1 and PC2 directly interact via a coiled-coil interaction (10) , and the complex has been shown to generate a unique Ca 2þ signal in transfected cells (11) . PC1 and PC2 are widely expressed in many embryonic and adult tissues and organs making it likely that they function together in most tissues. Expression of the cytosolic C-tail of PC1 stimulates a number of signaling pathways in transfected cells, leading to the activation of promoter reporters such as AP-1 and NFAT (12) (13) (14) (15) . The membrane-proximal region of the PC1 C-tail contains a heterotrimeric G-protein binding and activation domain (16) that initiates signaling by activating G i/o , G q/11 and G 12/13 (14) , and when injected into neuronal cells, PC1 has been shown to activate G i/o and release Gbc subunits that modulate ion channel activity (17) . Ciliary PC1 and PC2 have also been shown to mediate fluidflow mechanosensory, transient elevations in intracellular Ca 2þ in a ryanodine receptor-dependent fashion (18) . While it appears that PC1/PC2 form a signaling-responsive Ca 2þ channel, their ciliary mechanosensory actions and their biochemical and cellular functions are unclear (19) (20) (21) . Most mutations in PKD1 are loss-of-function, including deletions, splicing, frameshift and nonsense mutations, which would be expected to significantly alter PC1 protein levels (22) . Missense mutations have also been described that affect functional protein levels (23) ; however, other than revealing that PC1 biogenesis and protein levels are critical, these mutations do not provide insight into the biochemical functions of PC1. There are a number of C-tail single aa mutations associated with ADPKD including a cluster of mutations in the G-protein binding and activation region of the PC1 C-tail that might affect G-protein signaling without affecting other properties of PC1. One such mutation is a three base pair deletion resulting in the deletion of a single conserved leucine residue (DL) within the PC1 Ctail (24) .
In this study, we show that the DL mutation is one of several single aa mutations that significantly impairs G-protein signaling to AP-1 in transient transfection assays. Generation of a knock-in mutant mouse model (Pkd1 DL ) showed that this mutation causes a severe PKD phenotype. Homozygous Pkd1 DL/DL mice are embryo lethal, similar to truncating loss-of-function mutations, and combination of Pkd1 DL with a conditional Pkd1 deletion allele during embryonic development causes a severe cystic phenotype in pups. Although Pkd1 DL behaves like a null allele, normal levels of full-length PC1 DL protein product are made and produce GPS-cleaved and mature, glycosylated protein. The PC1 DL protein also forms complexes with PC2, yet is unable to support PC2 channel activity. As such, these experiments suggest that the G-protein binding and activation region of the C-tail is critical to PC1 function by regulating PC2 Ca 2þ channel activity.
Results

PKD1 patient mutations within the G-protein binding region affect PC1 signaling
We had previously demonstrated that the C-terminal tail of PC1 binds and activates heterotrimeric G-proteins (16) , and that PC1-mediated activation of JNK and AP-1 (12) is mediated by both Ga and Gbc subunits (14) . We also identified a polybasic G-protein activation domain ( Fig. 1 ) that promotes nucleotide exchange, located within a highly conserved region of the PC1 C-tail required for stable binding of G-proteins (16) . To determine whether mutations within this region affect PC1-mediated G-protein dependent signaling, we conducted a literature and database (pkdb.mayo.edu) (22) search to identify ADPKD patient mutations for further study. Our analysis identified a cluster of in-frame deletion or missense variants within 
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the G-protein binding domain in human PC1 (Supplementary Material, Fig. S1 ). To screen for function, corresponding mutations were introduced into a mouse PC1 C-tail fusion construct (sIg-PKD 222 ), and their effect on AP-1 activation was determined in transient transfection assays in HEK293T cells (14) . AP-1 activity was significantly stimulated by the WT sIg-PKD 222 construct but was reduced in cells expressing sIg-PKD 222 with patient mutations corresponding to L4132D, R4136T, R4136G (24) (25) (26) and engineered mutation R4135L (Fig. 2 ). An alanine substitution (L4132A) at the same site as L4132D did not have an effect on AP-1 activity (Supplementary Material, Fig. S2 ). These results show that mutations L4132D, R4135L, R4136T and R4136G interfere with AP-1 activation by the PC1 C-tail.
Previous work had shown that co-transfection of Ga subunits augmented AP-1 activation by WT sIg-PKD 222 (14, 15) . To determine if the patient mutations would have an effect on Ga augmentation of AP-1 activation, HEK293T cells were co-transfected with Ga 12 or Ga q and WT or mutant sIg-PKD 222 expression constructs. As previously observed, PC1-dependent AP-1 activity was augmented in cells co-expressing WT sIg-PKD 222 and Ga 12 (Fig. 2) . Ga 12 -augmented activity was reduced in cells expressing R4136T or R4136G. Activity was further reduced in cells expressing the R4135L mutation, and was eliminated in cells expressing the L4132D mutant. Similar results were observed with co-expression of Ga q (Supplementary Material, Fig. S3A ). Despite these pronounced effects on AP-1 activation, the mutant fusion proteins were able to interact and coimmunoprecipitate (IP) with co-transfected PC2 (Supplementary Material, Fig. S3B ), consistent with these mutations not disrupting the coiled-coil region of PC1. These results suggest that the mutations specifically impair the ability of PC1 to activate heterotrimeric G-protein signaling. Of all the mutations studied, L4132D had the strongest effect on PC1-dependent AP-1 activation and was selected for further analysis.
Generation of Pkd1
NEO DL and Pkd1 DL mice
The human mutation L4132D (DL) was identified in an ADPKD family. The mutation was found in all affected family members, but not the unaffected parent, suggesting that L4132D was the causative mutation in that family (24) . However, it could not be certain if this mutation was pathogenic, as the 5 0 coding region of the PKD1 gene was not examined for mutations in that analysis.
To determine whether the corresponding mouse DL mutation (L4122D) is sufficient to cause PKD, a targeting vector was constructed to introduce this mutation into mice using standard ES cell technology. Germline transmission of the Pkd1 NEO DL allele was observed in six founders, which were normal and viable. Proper integration of the targeting construct was verified by Southern blotting (Supplementary Material, Fig. S4 ).
To generate the Pkd1 DL allele, heterozygous Pkd1 NEO DL/þ mice were crossed to a Cre-deleter strain (EIIa-Cre) to excise the floxed NEO cassette leaving a single, remnant loxP site within intron 45 (27) . Excision was verified by genotyping using PCR primers that span the excised region and by sequence analysis (Supplementary Material, Fig. S4 ). (Fig. 3A) . To verify the presence of cysts in vivo, embryonic kidneys were isolated at E15.5 and analyzed microscopically. Early cyst formation, including glomerular cysts, was observed in these kidney sections (Fig. 3B ). Kidneys isolated from E15.5 pups and maintained in organ culture in the presence of 8-Br-cAMP developed large cystlike dilations consistent with a loss of PC1 function (Fig. 3C ).
Characterization of
To assess the effect of the DL allele on the growth and development of polycystic kidneys, and to circumvent the embryonic lethality, Hoxb7-Cre:Pkd1 DL/cond mice were generated (30,31).
Hoxb7-Cre:Pkd1 DL/cond mice were born and had enlarged kidneys and elevated kidney weight to body weight ratios by P9 (Fig. 3D ).
Kidneys became even more enlarged by P14, with cyst formation throughout the entire kidney ( Fig. 3E ), comparable to cystic kidneys obtained from Hoxb7-Cre:Pkd1 cond/cond mice (32). These results strongly suggest that the corresponding L4132D patient mutation is pathogenic.
Analysis of mutant PC1 protein
To determine how the DL deletion disrupts PC1 function, we asked whether the mutation affected PC1 expression or cleavage. Full-length WT, DL-mutated or coiled-coil truncating S4213X human PC1 proteins were expressed in HEK293T cells. Western blot analysis confirmed that the DL mutation did not affect PC1 protein expression levels, electrophoretic mobility or the ability of PC1 to undergo N-and C-terminal cleavage events (Fig. 4A ). Full-length DL-mutated PC1 retained the ability to interact with PC2 in HEK293T cells in co-IP experiments (Fig. 4B) , suggesting that the DL mutation does not disrupt the ability of PC1 to form complexes with PC2.
To determine whether the DL mutation affects cleavage or maturation of endogenous PC1 we examined membrane preparations from mouse embryonic fibroblasts (MEFs) isolated from E14.5 embryos. The preparations were treated with endoglycosidase H (EndoH; cleaves basic N-glycosides on immature proteins in the ER but is inactive toward glycosides on mature proteins processed in the Golgi) or peptide-N-glycosidase F (PNGaseF; cleaves oligosaccharides from both mature and immature proteins). Full-length protein, cleaved NTF and cleaved CTF were detected in Pkd1 DL/DL MEF membrane preparations, and all glycoforms responded to EndoH and PNGaseF treatment in a manner identical to that of WT PC1 from Pkd1 þ/þ MEF membranes ( Fig. 5A and B). In a similar analysis, we observed that the product of the Pkd1 NEO DL allele was smaller than full-length PC1, and was cleaved to produce a single immature NTF glycoform that was entirely EndoH-sensitive ( mutant. These truncation mutants are known to undergo GPS cleavage but fail to mature beyond the ER due to an inability to interact with PC2, which is required for full maturation of PC1 (33, 34) . This is in marked contrast to the mature, full-length DL protein.
To determine whether the DL mutation affects PC1 protein levels, we quantified the amount of the PC1 glycoforms (fulllength, mature and immature cleaved NTF) in membranes prepared from three independent WT and Pkd1 DL/DL MEF cultures.
The DL mutation did not affect the ratio of mature to immature NTF or the ratio of full-length PC1 relative to a membrane marker protein, ALIX, and there was only a small nonsignificant reduction in the amount of mature NTF relative to ALIX (Fig. 5C , and see discussion).
To determine whether the DL mutation affects PC1 intracellular membrane localization we analyzed protein from E14.5 whole embryo membrane preparations following fractionation over a heavy water/5-30% sucrose gradient (35) immature NTF, and the persistent presence of immature NTF toward the bottom of the gradient. These results suggest that the expression and membrane localization of PC1 DL is fundamentally identical to that of WT PC1. We also analyzed E14.5 embryonic kidneys for PC1 protein by immunoblotting. Fulllength and mature NTF were easily detected in membrane preparations ( Fig. 6 and Supplementary Material, Fig. S7A ), but not in whole-cell kidney lysates where immature NTF was the only PC1 glycoform detected (Supplementary Material, Fig. S7B ).
To confirm that PC1 DL protein was able to localize to the plasma membrane/cell surface, porcine LLC-PK1 cells were electroporated with constructs encoding GFP-tagged PC2 and either N-terminal mCherry-tagged WT PC1 or PC1 DL proteins (Fig. 7A ) (33) , and protein expression was confirmed in whole-cell lysates by immunoblot (Supplementary Material, Fig. S8A and B). PC1 was detected by immunofluorescence using antibody directed against the mCherry epitope tag under both non-permeabilized and permeabilized conditions (33) . Under non-permeabilized Endogenous PC1 levels were determined in MEF cultures isolated from three Pkd1 þ/þ and three Pkd1 DL/DL embryo littermates. The DL mutation did not affect the ratio of mature to immature NTF or the ratio of full-length PC1 relative to a membrane marker protein, ALIX, and there was only a small, non-significant (Student's t-test) reduction in the amount of mature NTF relative to ALIX. conditions, both WT and DL-mutated PC1 could be detected across the entire plasma membrane (Fig. 7B) . Incubation without primary antibody to mCherry showed no PC1 detection (Supplementary Material, Fig. S8C ). Under permeabilized conditions, both WT and DL-mutated PC1 were readily detected throughout the cell, with reduced immunofluorescence in the nuclear region (Fig. 7B) . To determine whether PC1 DL trafficked as efficiently as WT PC1, we counted the number of cells that were positive for GFP PC2, mCherry PC1 or both in 5-10 fields from the non-permeabilized condition of three independent transfection experiments. For both WT PC1 and PC1 DL , the majority of cells were positive for GFP PC2 only, and the percentage of cells positive for both GFP PC2 and mCherry PC1 was greater than for mCherry PC1 alone. Importantly, the total percentage of cells exhibiting surface expression of mCherry-PC1 DL (both with and without PC2) was essentially the same as for WT PC1 (Fig. 7C) . These results confirm that the PC1 DL protein is capable of trafficking to the cell-surface in a manner comparable to that of WT PC1. To determine if the DL mutation affects the ability of PC1 to regulate PC1/PC2 channel activity, we co-expressed human PC2 with either full-length WT PC1, PC1
DL or C-terminally truncated mutant PC1 S4213X in CHO cells and measured whole-cell macroscopic currents under voltage-clamp conditions (Fig. 8) .
Compared to cells expressing WT PC1, channel activity in cells expressing PC1 DL was reduced to levels comparable to that of cells expressing truncated PC1
S4213X
, which cannot interact with PC2 ( Figs 8A and 4B ). To verify that the channel activity in CHO cells is PC2 dependent, we showed that a PC2 channel mutant, D511V (9), blocked activity to the same extent as both the PC1 truncation mutant and PC1 DL (Fig. 8B) . Thus, it appears that the DL mutation inhibits PC1/PC2 channel activity without affecting the PC1/PC2 binding interaction.
Discussion
The majority of PKD1 mutations analyzed has been shown to affect PC1 protein biogenesis, trafficking or stability and have revealed little about the intrinsic biochemical or cellular functions of PC1. In theory, analysis of missense Pkd1 alleles has the potential to identify critical signaling domains and functional properties of PC1. We previously identified a highly conserved region within the C-terminal, cytosolic tail of PC1 that constitutes a minimal binding domain for heterotrimeric G-proteins Comparable transfection efficiency of the WT and DL constructs was confirmed by counting the number of cells positive for GFP, mCherry and GFP/mCherry signal as detected using permeabilized conditions (data not shown).
and contains a 20 aa peptide sequence capable of activating heterotrimeric G-protein nucleotide exchange (16) . To determine whether disruption of PC1-mediated activation of heterotrimeric G-protein signaling might be relevant to PKD, we analyzed ADPKD-associated missense mutations that lie in and around the G-protein activation domain using AP-1 activation as a surrogate for PC1-mediated heterotrimeric G-protein activity (14) . Human substitution mutations (R4135L, R4136T and R4136G) that removed the positive charge from the first two basic residues of the previously identified, polybasic G-protein activation peptide reduced PC1-mediated basal and Ga-augmented AP-1 activation without affecting the ability of PC1 to co-IP with PC2. Similar results were obtained for the single aa deletion L4132D (DL). Secondary structure algorithms (NPS@ and PORTER) (36, 37) predict that L4132 lies within an amphipathic helix contiguous with and including the G-protein activation peptide. As such, deletion of L4132 would likely offset the distribution of multiple side-chain residues that could be important for PC1-mediated activation of heterotrimeric G-proteins ( Supplementary  Material, Fig. S9 ). An L4132A substitution at the same location, which we predicted would not alter the overall side-chain charge distribution, had no effect on PC1-mediated AP-1 activity.
We also noted the frequency of ADPKD-associated mutations affecting the G-protein activation domain ( Supplementary  Material, Fig. S10 ). While it may appear that there are no strong mutational hotspots when all loss-of-function mutations throughout the PKD1 gene are considered (38) , our analysis indicates that within the C-tail region there is a clustering of patient mutations within and around the conserved G-protein activation domain. Of the mutations studied here, human mutation L4132D (24) had the largest impact in an AP-1 transcriptional assay, blocking both basal and Ga-augmented activity. We selected this mutation for further analysis to determine pathogenicity and to gain insight into the importance and relevance of PC1-mediated G-protein signaling to PKD.
In all aspects tested, the Pkd1 DL allele behaves as a null allele. revealed that it is expressed and undergoes GPS cleavage. However, the resulting cleavage products are sensitive to EndoH, indicating that it is unable to egress from the ER (34) . As such, all three of these missense Pkd1 alleles have PKD phenotypes because of decreased levels of mature, cleaved protein.
While the disease severity of the Pkd1 DL allele is comparable to that of Pkd1 m1Bei and to Pkd1 null alleles, our analysis of the PC1 DL protein reveals that there is at most only a small and non-significant decrease in the overall level of mature NTF. While this small reduction in mature NTF could in principle influence cystogenesis, it cannot account for the lethal phenotype. In a comparable experiment (33), MEFs isolated from Pkd1 þ/À embryos, which do not develop cystic disease, exhibit a greater reduction ($50%) in mature NTF, establishing this as a threshold for sufficient PC1 function. MEFs isolated from Pkd1 RC/RC embryos, which will develop only mild cystic disease as adults, exhibit a $65% reduction in mature NTF. In contrast, MEFs derived from severely cystic (embryo lethal) Pkd1 DL/DL embryos have mature NTF levels that are well above these threshold levels, indicating that the embryonic lethality caused by the DL mutation cannot be explained by a reduction in PC1 DL expression relative to WT PC1. Further evidence suggesting that PC1 DL protein expression and localization are comparable to those of WT PC1 was obtained by analyzing native protein in whole embryo membrane preparations and in embryonic kidney lysates; and by analyzing proteins transiently expressed in porcine kidney epithelial cells. In all of these assays, the levels of PC1 DL expression, its fractionation profile, and its cellular localization were comparable to that of WT PC1. This was in marked contrast to the behavior of the protein produced from the Pkd1 DL precursor allele, Pkd1
NEO DL , which does not produce appreciable levels of mature NTF, and has a different membrane fractionation profile. As such, our results indicate that the DL mutation disrupts a critical biochemical function of PC1.
In the current study, we sought to determine whether the DL mutation would affect the channel activity of PC2. Several lines of evidence suggest that PC2 channel activity might be affected by alterations in the ability of PC1 to activate heterotrimeric Gprotein signaling (17, 40) . CHO cells expressing full-length PC1 and PC2 exhibited significantly higher channel activity than cells expressing PC2 and a C-terminally truncated PC1
S4213X that cannot interact with PC2, or cells expressing PC1 and PC2 channel mutant, D511V (9), indicating that this channel activity requires the PC1/PC2 complex. Cells expressing full-length PC1 DL and PC2 had current levels comparable to that of channel-inactive PC1 S4213X /PC2 or PC1/PC2 D511V cells. We believe that in these experiments the loss of PC2 channel activity occurs from an inability of the PC1 DL mutant to initiate G-protein signaling.
A disruption in PC1-mediated heterotrimeric G-protein signaling could potentially alter PC2 channel activity by several different mechanisms. For instance, PC2 localization and channel activity are regulated by phosphorylation (7, (41) (42) (43) , IP 3 -induced Ca 2þ release (44) , and membrane lipid composition and intracellular Ca 2þ (45) (46) (47) . Each of these regulatory mechanisms involves second-messenger-dependent signaling that may be downstream of PC1-mediated G-protein signaling. PC2 could also be regulated through direct interactions with G-protein subunits activated by PC1. There are numerous examples of Gprotein subunits directly regulating channel protein activity (48, 49) , a possibility that remains to be explored for PC2. Given these potential mechanisms, we speculate that the inability of the PC1 DL mutant to initiate G-protein signaling may result in an otherwise structurally normal PC1/PC2 complex that is functionally impaired. Additional questions remain concerning the role of heterotrimeric G-protein signaling in PKD. Wu et al. demonstrated that in mice, Pkd1 knockout leads to increased Ga 12 activation, and genetic deletion of Gna12 blocks cystogenesis induced by deletion of Pkd1. In this model, PC1 is hypothesized to antagonize cystogenesis via its ability to sequester Ga 12 subunits in an inactive state (50) . In a more recent study, Zhang et al. demonstrate a PKD phenotype in the Xenopus pronephric kidney following loss of the G-protein a subunit Gnas. However, this phenotype is antagonized by pharmacological and genetic inhibition of Gbc signaling, suggesting that loss of Gnas leads to increased, cystogenic Gbc signaling (51) . Both of these results are in contrast with our model of PC1 signaling, which predicts that loss of PC1 signaling results in cystogenesis due to decreased heterotrimeric G-protein signaling. At this point it is difficult to reconcile these seemingly disparate models of PC1 function, but a common theme between Wu et al., Zhang et al. and our present findings is the central importance of the PC1 G-protein binding domain to regulate heterotrimeric G-protein signaling (14, 16) .
In conclusion, our results have implications for treatment of PKD, as therapies designed to mimic or restore G-protein-mediated activation of PC2 may be sufficient to counteract cystogenesis in cases where PC1 is not expressed or incapable of activating G-proteins. Likewise, signaling mutants such as PC1 DL may be exquisitely responsive to small-molecule therapy designed to act specifically on inactive PC1/PC2 receptorchannel complexes. Future efforts should focus on revealing the molecular dynamics of the PC1/PC2 complex and the mechanisms by which PC1-activated G-protein subunits may regulate PC2 channel activity.
Materials and Methods
Detailed methods are available as supplementary material.
Plasmids
Plasmid sIg-PKD 222 and sIg-0 were described previously (14) .
Mutations were introduced as previously described (52 (27) . A floxed NEO cassette from pNTL (53) was inserted into intron 45, and the DL mutation was introduced with a QuikChangeII SiteDirected Mutagenesis Kit (Stratagene). All cloning manipulations were verified by DNA sequencing.
Cell culture, AP-1 assays, IP and Western blotting HEK293T (ATCC) cells were transfected as described previously (14, 15) . AP-1 activity was determined with the dual luciferase assay kit (Promega) using an EG&G Berthold 9507 Luminometer. For co-IP following dual luciferase, sIg proteins were precipitated with EZ-View Protein A beads (Sigma) and proteins detected as described previously (14, 52) . For co-IP of full-length PC1 and PC2, HA-tagged PC1 was precipitated with agaroseconjugated HA-probe (F-7; Santa Cruz Biotech).
ES cell production
The targeting vector was linearized and electroporated into 129/ Ola parental cells by the University of Kansas Medical Center Transgenic and Gene-Targeting Institutional Facility. Neomycin resistant clones were screened by long-range PCR. Positive clones were expanded and karyotyped, and proper recombination was verified by Southern blotting.
Southern blotting
ES cell or mouse tail DNA was isolated with the Wizard Genomic DNA Purification Kit (Promega), digested with BglII, and electrophoresed and detected by Southern blotting. Probe DNA was generated by PCR amplification of WT ES cell DNA. The product was cloned into pGEM-T (Promega), and an $800 bp NcoI fragment was labeled using the AlkPhos DIRECT kit (GE Healthcare).
Mice
Super-ovulated C57BL/6 females (The Jackson Laboratory) were mated to C57BL/6 males. Blastocysts were injected with Pkd1 NEO DL targeted ES cells and transferred to recipient CD-1 females (Charles River Laboratories). Chimeric mice were identified by agouti coloration and mated to C57BL/6 mice to obtain germline transmission. Agouti pups were genotyped by PCR and the presence of the Pkd1 NEO DL allele was verified by Southern. 
Pkd1
Organ culture
Metanephroi were dissected from embryonic mice and lysed in SDS-PAGE sample buffer or PC1 lysis buffer (Supplementary methods) for immunoblot analysis, or cultured 6100 mM 8-BrcAMP and analyzed as described previously (29) .
Mouse embryonic fibroblasts (MEFs)
Genotyped embryo carcasses were minced and digested twice with trypsin. Cells were maintained in DMEM (Cellgro) containing additional L-glutamine (2 mM) and 100 000 units penicillin/ 100 mg streptomycin per liter supplemented with 10% heatinactivated fetal calf serum. Genotypes were verified after the first passage.
Deglycosylation assays
Total cellular membranes were purified from hyper-confluent MEF cultures as previously described (33) with minor modifications. Membrane fractions were treated with EndoH or PNGaseF (Promega) according to manufacturer's instructions with minor revisions.
Membrane preparation and sucrose gradient centrifugation E14.5 embryos in lysis buffer were disrupted by polytron, Dounce homogenization and sonication. Membranes were clarified by gentle centrifugation, equilibrated and applied to a heavy water/5-30% sucrose gradient (35) and centrifuged at $274 000g for 16 h in a Sorvall TH-641 rotor. Gradient fractions were collected from the top down using a BioComp fraction collector. The refractive index of each fraction was determined, and proteins were detected by immunoblotting.
Immunofluorescence
Porcine LLC-PK1 cells were electroporated (Nucleofector II; Amaxa with Basic Nucleofector Kit for Primary Mammalian Epithelial cells; Lonza) with pTAG GFP PC2 and mCherry PC1 constructs, and surface and intracellular expression of WT and DL-mutated PC1 was detected by immunofluorescence using antibody directed against the mCherry epitope (33). Images were obtained with an Eclipse TE2000-U microscope (Nikon) using a 60Â oil objective and Image-Pro Premier (MediaCybernetics) and Photoshop (Adobe) software. For quantification, images were taken of 5-10 non-overlapping fields (20Â objective) that contained GFP-positive cells. The same fields were subsequently imaged for Texas Red, and the number of cells positive for GFP, Texas Red or both was determined. Quantification was from three independent transfection experiments.
Electrophysiology
CHO cells (ATCC) were transfected using Polyfect reagent (Qiagen) as described previously (40, 54) with green fluorescent protein (pEGFP-F; TaKaRa Clontech) and full-length PC1/PC2 expression constructs. Whole-cell macroscopic recordings of PC1/ PC2 channel activity were made under voltage-clamp conditions on EGFP-positive cells 48-72 h after transfection as previously described (11, 55) with an Axopatch 200B amplifier (Molecular Devices) interfaced via a Digidata 1440 (Molecular Devices) to a PC running the pClamp 10.3 software suite (Molecular Devices).
Secondary structure prediction analysis
Predictions were performed using NPS@ (Network Protein Sequence Analysis; https://npsa-prabi.ibcp.fr; date last accessed May 6, 2018) (36) and PORTER (37) . Helical wheel projection analysis and hydrophobic moment calculations were performed at http://rzlab.ucr.edu/scripts/wheel/wheel.cgi; date last accessed May 6, 2018 (56) .
Statistics
Data are means 6 SE. Statistical significance was determined by one-way ANOVA and Student-Newman-Keuls (S-N-K) posttest for multiple comparisons.
Supplementary Material
Supplementary Material is available at HMG online.
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